We had previously defined by allele loss studies a minimal region at 6q27 (between D6S264 and D6S297) to contain a putative tumour suppressor gene. The p90 ribosomal S6 kinase-3 gene (p90 Rsk-3, RPS6KA2) maps in this interval. It is a serine-threonine kinase that signals downstream of the mitogen-activated protein kinase pathway. It is expressed in normal ovarian epithelium, whereas reduced or absent in tumours or cell lines. We show that RPS6KA2 is monoallelically expressed in the ovary suggesting that loss of a single expressed allele is sufficient to cause complete loss of expression in cancer cells. Further, we have identified two new isoforms of RPS6KA2 with an alternative start codon. Homozygous deletions were identified within the RPS6KA2 gene in two cell lines. Re-expression of RPS6KA2 in ovarian cancer cell lines suppressed colony formation. In UCI101 cells, the expression of RPS6KA2 reduced proliferation, caused G1 arrest, increased apoptosis, reduced levels of phosphorylated extracellular signal-regulated kinase and altered other cell cycle proteins. In contrast, small interfering RNA against RPS6KA2 showed the opposite effect in 41M cells. The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27.
Introduction
Chromosome 6 has been implicated to contain a putative tumour suppressor gene important in the pathogenesis of ovarian cancer, both by karyotypic analysis and allele loss studies (Shelling et al., 1995; Liu and Ganesan, 2002) . Initially, a minimal region of allele loss was delineated between D6S193 and D6S149 (1.9 cM, 0.6 Mb) on chromosome 6q based on one tumour (Saito et al., 1992) . We showed previously that the minimal region of allele loss was between D6S297 and D6S264 (3 cM, 0.6 Mb) based on analysis of 56 ovarian tumours (Cooke et al., 1996a, b; Liu et al., 2002b) . The maximal frequency of allele loss occurred at D6S193 (62%) and D6S297 (52%), which are 55 kb apart. Three tumours showed loss of D6S193 only, while retaining flanking markers thus suggesting that the putative tumour suppressor gene was located close to D6S193. The allele loss was observed in all types of epithelial ovarian cancer. This was further confirmed by examination of another panel of tumours (ChenevixTrench et al., 1997) . Further evidence of a putative tumour suppressor gene located near the marker D6S193 was suggested by fluorescent in situ hybridization studies using yeast artificial chromosome (YACs) on direct metaphase spreads from fresh ovarian tumours that demonstrated that this change might be important even in early ovarian tumours (Tibiletti et al., 1996 (Tibiletti et al., , 1998 (Tibiletti et al., , 2000 .
We constructed a genomic and transcript map around the polymorphic markers in order to identify the gene on chromosome 6q27 by positional cloning. An overlapping bacterial contig covering the overall region of allele loss encompassed by the markers D6S264 and D6S149 (1.2 Mb) was constructed. The detailed analysis of this region has been published previously (Liu et al., 2002a, b) . We showed the gene p90 Ribosomal S6 kinase-3 (p90 Rsk-3, RPS6KA2) mapped within 150 kb of the marker D6S193, the only confirmed gene between the markers D6S297 and D6S264.
We report here the analysis of RPS6KA2 in ovarian cancer cell lines and tumours. There is loss of expression in ovarian tumours and cell lines. The reason for this loss of expression was not due to inactivating mutations within the coding region. Although methylation of the promoter might be a probable mechanism in some cell lines, we were unable to demonstrate this directly by bisulphite sequencing of the predicted promoter. However, we show that the human gene is monoallelically expressed in the normal ovary. This suggests that loss of the single expressed allele may be sufficient to render complete loss of expression in cancer cells. Further, we show by different approaches that re-expression of RPS6KA2 in cell lines reduced proliferation, suppressed colony growth and arrested cells in G1 phase of the cell cycle with significant increase in apoptosis. The kinase activity of RPS6KA2 is essential for its antiproliferative effect, but the biochemical mechanism is as yet unknown.
Results

Mapping of RPS6KA2 at 6q27
We had previously mapped a region of allele loss between D6S264 and D6S149 at chromosome 6q27 in sporadic ovarian cancer (Cooke et al., 1996a, b; Liu et al., 2002b) . The order of the genes located between D6S264 and D6S149 (1.2 Mb) is D6S264-RPS6KA2-D6S193-D6S297-RNASE6PL-FOP-CCR6-GPR31-TCP 10-UNC93-D6S149. RPS6KA2 was the only confirmed gene that mapped between D6S264 and D6S297, which was the minimal interval of allele loss defined by us previously (Supplementary Figure 1) . The gene for RPS6KA2 is 215 kb in size, contains 21 exons and is approximately 150 kb from D6S193. The first exon is unique to RPS6KA2 in comparison with the other members of the RSK family. Exon 1 contains the nuclear localization signal and is separated from the second exon by a large intron of approximately 88 kb. The first catalytic domain, which is homologous to the c-AMP family of kinases, is coded for by exons 2-10. The second catalytic domain, which is homologous to the phosphorylase kinase family, is encoded by exons 14-19. In general, splice donor and acceptor sites observed the AG/GT rule.
Expression of RPS6AK2
The expression of RPS6KA2 has been reported previously using probes from the 3 0 untranslated region (Moller et al., 1994) . Hybridization of a multiple tissue Northern blot with the full-length RPS6KA2 cDNA (Acc. no. X85106) showed expression of the gene in the normal ovary in addition to other tissues ( Figure 1a ). The size of the major transcript was approximately 6.2 kb, identical to that previously reported, although the initial cDNA clone was only 2790 bp (Moller et al., 1994) . In addition, there was a smaller transcript of 4.4 kb in the small intestine, ovary and testis. A further minor transcript of 3.2 kb was observed in the testis. The size of the longer transcript correlates with the size of the updated mRNA transcript in the NCBI database (NM_021135) of 5817 bp; whereas the origin of shorter transcripts detected is unknown, but could be processed transcripts. The RPS6KA2 transcript was weakly detected in a Northern blot in two cell lines (41M and OAW28) whereas there was no detectable expression in the remainder (Figure 1b ). This result was further verified by ribonuclease protection assays using exons 1 and 2 (nucleotides 175-390, Acc. no. X85106) in the antisense orientation as probes (data not shown).
RPS6KA2 is expressed in all human tissues (Figure 1c ) from the public microarray expression data (http://symatlas.gnf.org/SymAtlas/) (Su et al., 2002) . In particular, RPS6KA2 is expressed in the ovarian epithelium when compared to the other closely related kinases RPS6KA1 and 3 (Figure 1d ).
Levels of RPS6KA2 transcript were assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) from first strand cDNA, using primers for exons 1 and 2 (Figure 1e ). RPS6KA2 transcript was detected at higher levels in placenta than in ovary cDNA (8 versus 2.5 times) relative to the immortalized human ovarian surface epithelium (HOSE) cell line. Although most of the cell lines expressed relatively low levels of RPS6KA2 transcript compared to HOSE (1-5 times), only one cell line (UCI101) had undetectable transcript levels. The cell line 41M expressed the RPS6KA2 transcript at similar high levels as the placenta (>9 times) concordant with the Northern analysis. Protein expression was examined in the same panel of ovarian cancer cell lines using specific antibodies to the RPS6KA2 protein . No RPS6KA2 protein was detected in lysate samples or after immunoprecipitations, although RPS6KA1 and RPS6KA3 were detectable in the cell lines (data not shown). We then examined a panel of 25 malignant epithelial ovarian tumours for expression of RPS6KA2 by RT-PCR (Table 1) . The tumours were all derived from patients with ovarian cancer and are composed of different stages, histological types and grades. Using primers that amplify exons 1 and 2 of RPS6KA2, we were able to detect expression in only 9/25 tumours ( Figure 1f ).
RPS6KA2 and methylation
No mutations were detected in the entire coding sequence of RPS6KA2 using Single-Strand Conformation Polymorphism (SSCP), Denaturing High Performance Liquid Chromatography (DHPLC) and direct sequencing, in malignant ovarian tumours (n ¼ 30), or in the panel of ovarian cancer cell lines (n ¼ 8) (data not shown). However, polymorphisms were detected in different exons (exon 8 c.681A>G, exon 12 c.1002G>A and exon 14 c.1311A>G).
To evaluate the causes for loss of expression of RPS6KA2, we examined methylation of promoter elements as a mechanism. Treatment of the UCI101 cell line with an increasing amount of the demethylating agent 5-azacytidine (1-5 mM) produced detectable levels of the RPS6KA2 transcript by RT-PCR in comparison with the untreated cell line (Figure 2a) , suggesting that the RPS6KA2 locus in UCI101 is intact at the genomic level, its competent for transcription and the gene is silenced by methylation. When the panel of ovarian cancer cell lines were treated with 5-azacytidine (at 5 mM), increased levels of expression were detected in four other cell lines. 41M, PE04, OAW28 and HOSE expressed higher levels of RPS6KA2 transcript compared to the untreated cells, whereas no difference was observed for the rest of the cell lines ( Figure 2b ). As methylation of the promoter region is a common mechanism for loss OAW28  SKOV3  OVCAR3  PE04  OAW42  41M  59M  UCI101  HOSE  JAMA2  OVARY  PLACENTA  0   5   10   15   OV167   PLACENTA   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  no RT  no cDNA   100 showing the distribution of the RPS6KA2 transcript across human tissues (Su et al., 2002) . The vertical line represents the median for the complete set of samples. (d) Subset of microarray expression data, showing higher levels of RPS6KA2 transcript in ovarian epithelium compared to the expression of the other RPS6KA members for which public data were available. (e) Relative quantification of transcript level of RPS6KA2 in a panel of ovarian cancer cell lines using qRT-PCR. cDNA was obtained after reverse transcription from 1 mg of RNA. An amplicon of 100 bp was amplified using the primers RPS6KA2c-qF and RPS6KA2c-qR and detected using qRT-PCR. Transcript levels were normalized to the GAPDH level for each sample and referenced to levels in the HOSE cell line.
(f) RT-PCR on RNA from ovarian tumour samples showing expression of RPS6KA2 in 9/20 samples only, using primers NF1 and NR1 (top panel). GAPDH amplification on the same samples was used for loading control and assessing mRNA integrity (bottom panel).
of expression, the upstream region of the start site of RPS6KA2 was analysed to identify the promoter region of this gene. A bioinformatics approach utilizing 10 different promoter prediction programs including GenomatixSuite (www.genomatix.de) and Methprimer (Li and Dahiya, 2002) were used to analyse 10 kb upstream of the RPS6KA2 gene and its first exon and intron. Two CpG islands were identified upstream of the RPS6KA2 start site (À1580 to À1388 and À1134 to À54 relative to the start site of Acc. no. X85106), the latter one coinciding with a predicted promoter region. Sodium bisulphite-treated genomic DNA from placenta samples (control) and from UCI101, 41M and OAW28 cell lines were fully sequenced but no methylated CpGs were identified (data not shown). Methylation was detected at the same time in control DNA treated with CpG methylase.
Monoallelic expression of RPS6KA2 Eight polymorphisms within the mRNA sequence of RPS6KA2 were analysed in the genomic DNA from human normal tissues and ovarian cancer cell lines. Polymorphisms in exon 2 (c.108C>T), exon 12 (c.1002G>A) and exon 14 (c.1311A>G) were informative in normal tissue DNA. Subsequent sequencing of cDNA obtained from these samples showed monoallelic expression of RPS6KA2 in the normal ovary and heart ( Figure 2c ). However, the normal liver and lung showed biallelic expression as indicated by the presence of an exon 12 polymorphism in the paired DNA and cDNA samples (Figure 2d ).
To evaluate whether RPS6KA2 is imprinted, we identified three families (CEPH) in whose DNA there were informative polymorphisms (exon 2, c.108C>T) in the parents and child. PCR amplification and sequencing of the genomic DNA and mRNA (encompassing the polymorphisms) from Epstein-Barr virus-transformed lymphoblastoid cell lines did not show any evidence for imprinting in all three families (data not shown).
RPS6KA2 inhibits growth in ovarian cancer cell lines Colony formation assays were performed to examine the effect of ectopic expression of RPS6KA2 in ovarian cancer cell lines. Significant inhibition (from Po0.05 to Po0.001) of colony formation in comparison with vector control (Figure 3a and representative plates in Figure 3d ) was observed for the cell lines that have low or undetectable levels of RPS6KA2 transcript (SKOV3, UCI101, OVCAR3, OVCAR4). In contrast, transfection of RPS6KA2 did not produce colony growth inhibition compared to control in the OAW28 or 41M cell lines, which express RPS6KA2. We then evaluated whether there might be a toxic effect from overexpression of the kinase; no inhibition was observed when performing the same experiment with RPS6KA1, RPS6KA3 or RPS6KA6 in UCI101, which does not express RPS6KA2 (Figure 3b ). This confirmed that the colony inhibition effect was specific for RPS6KA2. We verified that all proteins were expressed ( Figure 3c ).
We were unable to establish stable cell lines constitutively expressing RPS6KA2 in UCI101. Therefore, we established doxycycline (DOX)-inducible stable cell lines expressing RPS6KA2 in UCI101. This cell line was chosen as RPS6KA2 expression is undetectable and it produces colonies in soft agar assays (Fuchtner et al., 1993) . As a control and to evaluate whether the catalytic activity of RPS6KA2 was required to inhibit growth, we established an inducible cell line expressing the mutant K91A-RPS6KA2, which is catalytically inactive . RNASE6PL is the adjacent gene telomeric to RPS6KA2 (Supplementary Figure 1) , which has been suggested as a putative class II tumour suppressor gene (Acquati et al., 2001) . As an additional control, we expressed RNASE6PL inducibly in UCI101 background. Despite several attempts it proved difficult to select and maintain individual clones of UCI101 expressing wild-type RPS6KA2.
Anchorage-independent assays were performed with two independent clones for the stable cell line UCI101/ TR/K91A-RPS6KA2 and UCI101/TR/RNASE6PL and the parental UCI101/TR, whereas one clone and two different pools of clones were used for UCI101/TR/ RPS6KA2. A reduced number of colonies were detected in UCI101 cells expressing RPS6KA2 under DOX induction (Po0.001, Figure 3e ) compared to cells where expression was not induced. The kinase activity of RPS6KA2 is essential for this inhibitory effect, as expression of the kinase-inactive mutant (K91A-RPS6KA2) did not show a significant difference. In control cells, containing only the repressor plasmid (parental) or expressing RNASE6PL, the presence of DOX or the expression of RNASE6PL did not affect the number of colonies formed. All the cell lines expressed the relevant protein when induced with DOX ( Figure 3f ).
Reduced proliferation of RPS6KA2-expressing cells
To examine the biological effect of RPS6KA2, we expressed RPS6KA2 and the kinase-inactive mutant using an adenovirus system. AdRPS6KA2 was used to infect the UCI101 cell line in order to obtain high levels of RPS6KA2 expression. Reduced proliferation was detected for the cell line when infected with adenovirus expressing RPS6KA2 but not when expressing K91A-RPS6KA2 or the null adenovirus (Po0.01, Figure 4a ). High levels of protein expression were confirmed by Western blotting in cells harvested at 120 h post-infection ( Figure 4a , right panel). This further confirmed that the kinase activity was essential for the growth arrest. Infected cells expressing RPS6KA2 were arrested at the G1 phase, as detected by fluorescence-activated cell sorting (FACS) analysis (Figure 4b) . A statistically significant increase of over 30% of cells (Po0.01) was found to be in G1/0, with a similar decrease in the number of cells in S and G2 phases of RPS6KA2-expressing UCI101 cells. Kinase-inactive K91A-RPS6KA2, nulladenovirus-expressing cells and mock-infected cells were not arrested at the G1 phase, suggesting that it is the presence of the active kinase that is responsible for this arrest.
To further examine whether expression of RPS6KA2 in UCI101 cells leads to cell death, we analysed for apoptosis using the CaspaTag system. This assay measures activated caspases using a fluorescent approach. Apoptosis was significantly increased in cells expressing RPS6KA2 (Po0.01) and p16 as measured by the increased number of cells labelled with the apoptotic indicator ( Figure 4c , bottom right quadrants) compared to controls. The p16, which is a tumour suppressor gene, was used as a control as shown previously (Schreiber et al., 1999) .
We performed experiments to understand how reexpression of RPS6KA2 in UCI101 altered key proteins involved in the cell cycle. As a positive control, we used an adenovirus expressing p16, which is a bona fide tumour suppressor gene. Adenovirus p16 has been used in similar assays (Schreiber et al., 1999) . Proliferative signal of phosphorylated extracellular signal-regulated kinase (ERK) was not detected in cells expressing RPS6KA2 or p16 ( Figure 5a ) in contrast to noninfected cells or cells infected with the kinase-inactive mutant or the null adenovirus. This confirmed the observation of the proliferation assays. The results revealed a reduced level of cyclin proteins and cyclinkinases (like cyclin D1, cyclin B, cdk1 and cdk2) involved in G1 phase in UCI101 cells infected with adenovirus expressing RPS6KA2 or p16. This was not observed in cells expressing the null adenovirus or mock-infected cells ( Figure 5a ). However, there were increased levels of cell cycle kinase inhibitors (p21 cip1 and p27 kip1 ) in UCI101 cells expressing RPS6KA2. The levels of Rb were reduced in the RPS6KA2-infected cells, similar to that of p16. There were reduced levels of Rb and cdk1 for cells expressing the kinaseinactive K91A-RPS6KA2, intermediate to that detected by cells expressing RPS6KA2. Decreased levels of precursor of caspase 3 and increased levels of cleaved poly (ADP ribose) polymerase (PARP) proteins ( Figure 5a ) were observed, validating the higher levels of apoptosis observed in RPS6KA2 and p16 infected cells.
To verify this effect in the cell cycle proteins, we knocked down the endogenous RPS6KA2 in 41M ovarian cancer cell line using small interfering RNA (siRNA). Levels of RPS6KA2 transcript were reduced to 20% when cells were transfected with oligo siRNA targeted to RPS6KA2 compared to control oligo siRNA (scrambled siRNA) or mock transfected ( Figure 5c ). Immunoblots of lysates of 41M cells transfected with oligo siRNA showed increased levels of phosphorylated ERK, increased protein levels of Rb and cdk2 and reduced levels of p21 when compared to control siRNA or mock-transfected cells ( Figure 5b ). We confirmed the specificity of those results using an nonspecific control oligo siRNA and a second oligo siRNA targeted to a different region of RPS6KA2, for which similar knockdown levels were obtained (data not shown). Taken together, these results were opposite to those obtained when RPS6KA2 was overexpressed.
Isoforms of RPS6KA2
While the experiments described above were in progress, an additional 5 0 mRNA sequence containing an alternative start codon for human RPS6KA2 was identified by oligocapping (http://dbtss.hgc.jp/) (Suzuki et al., 2004) . The same alternative start codon was also identified and conserved in the sequence of the Macaca fascicularis (Acc. no. AB060213). The alternative ATG lies 235 kb telomeric to the previous start codon of RPS6KA2 (Supplementary Figure 2a) . The two new isoforms (RPS6KA2a and b) encode for a protein with a different N-terminal domain, but shares the amino-acid sequence encompassing the two kinase domains and the linker region of the original RPS6KA2 (RPS6KA2c). Only one of the newly discovered isoforms (RPS6KA2a) is included in the NCBI database (update of 02/03/05, NM_001006932, RSK6KA2 variant 2).
Of the new exons identified, exon 1 (402 bp) and exon 2 (60 bp) are relatively close to each other, whereas 88 kb separates them from exon 3 (50 bp); 232 kb separates the new exons and the rest of the known gene at exon 4 (originally exon 2 for RPS6KA2c) (Supplementary Figure 2a) . The new isoforms also differ at the C-terminus, comprising 25 exons in total with three exons after the stop codon. In contrast, the previously isolated RPS6KA2 gene has 21 exons with a longer and experimentally determined 3 0 untranslated region. The relative level of expression of RPS6KA2a/b versus c based on Expressed Sequence Tags (EST) sequences in the database is 1:357; and quantification by qRT-PCR suggested that the isoforms RPS6KA2a/b represent o1% of the amount of RPS6KA2c in HOSE and 41M cell lines (data not shown), close to the limit of detection for those transcripts.
RPS6KA2a and RPS6KA2b contain 758 and 741 amino acids and differ in that exon 3 is spliced out; the theoretical sizes of the encoded proteins are 85.6 and 84.9 kDa, respectively ( Figure 6a ). The new RPS6KA2 isoforms were cloned and expressed in HEK293 cells 5 cells were seeded, transfected and grown in selective media for 2-3 weeks. Colonies formed were counted and the results of three different experiments in triplicate were combined; the bar graph shows the average and SE of those experiments. Colony numbers in RPS6KA2 were compared with empty pcDNA3.1 vector transfection; significant differences were observed for UCI101, OVCAR4, SKOV3 and OVCAR3 only (*for Po0.05, **for Po0.01 and ***for Po0.001). (b) Clonogenic assays of UCI101 cell line transfected with RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6 or empty vector, performed as described above. Results of three different experiments in triplicate were combined; the bar graph shows the average and SE of those experiments. Only RPS6KA2 transfection produced a significant (**for Po0.05) reduction in colony formation. (c) Cell lysates (from the clonogenic assays) of transfected cells with RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6 or empty vector were analysed by immunoprecipitation with HA antibody and detection by Western blotting with HA-HRP antibody. (d) Clonogenic assays of UCI101 cell line transfected with RPS6KA2. Representative dishes of transfected cells expressing RPS6KA2 or empty vector where cells were fixed and stained with Coomassie blue solution; darker staining represents a higher number of colonies. (e) Anchorage-independent assays of inducible stable cell lines. 2500 cells were seeded for soft agar assays. DOX was used for protein induction at 100 ng/ml for UCI101/TR/RPS6KA2 pool and UCI101/TR parental cell line, 50 ng/ml for UCI101/TR/K91A-RPS6KA2 and 1 ng/ml for UCI101/TR/RNASE6PL. Dishes were incubated for 10-14 days, colonies stained with 0.005% crystal violet and counted. Results of three different experiments in triplicate were combined; the bar graph shows the average and SE of three experiments. The colony count was normalized to uninduced cells (no DOX). A significant difference was observed only for the cell line expressing RPS6KA2 (***for Po0.001). (f) 5 Â 10 4 cells were harvested after 48 h of induction with DOX (DOX concentration as in (e) and the expressed protein was immunoprecipitated from lysates with HA antibody and detected by Western blotting with HA-HRP antibody. RPS6KA2 and K91A-RPS6KA2 (85 kDa) and RNASE6PL (45 kDa) were only detected in the induced ( þ DOX) samples. and were detected with appropriate antibodies. The commercially available antibody Rsk-3 N-16, with an epitope located at the N-terminus of RPS6KA2, detects exclusively the RPS6KA2c isoform, whereas the antibodies whose epitope lies at the C-terminus of RPS6KA2 (Rsk-3 C-20 and A-16) are nonspecific for the different isoforms and recognize all three proteins (Supplementary Figure 2b) .
The presence of the transcript for RPS6KA2a and b isoforms was determined by RT-PCR in the ovarian cancer cell lines UCI101, 41M, HOSE, OV167 and HEL (Figure 6b , bottom panel). Although UCI101 does not express any of the RPS6KA2 isoforms, RPS6KA2a was detected in HOSE, 41M and OV167 using two forward primers that annealed to exon 1 and exon 2, and RPS6KA2b in 41M, HOSE and HEL, using a forward primer that anneal to exon 3. The HEL cell line was found to have a homozygous deletion of exon 2 ( Figure 6b , top panel) and this was confirmed at the RNA level by the lack of transcript of RPS6KA2a, with primers annealing to this exon. The absence of a transcript for RPS6KA2b, containing exon 3, in OV167 correlates with the absence of amplification of exon 3 (Figure 6b , top panel) as part of the homozygous deletion of 80 kb detected at the DNA level (Lin and Morin, 2001 ). However, in both HEL and OV167, despite the genomic homozygous deletion in exons 2 and 3, respectively, there was presence of transcript encoded by RPS6KA2c. In order to identify the level of expression of the longer isoform of RPS6KA2 in human tissues, a panel of first strand cDNA from human tissues was used as template for PCR and a pair of primers that annealed to exons 2 and 4 of RPS6KA2a. Expression of RPS6KA2a is widely distributed in the tissues tested, as is the RPS6KA2c isoform (Figure 6c ).
We screened a panel of ovarian cancer cell lines (10) and tumours (50) for mutations by direct sequencing and DHPLC. No mutations were identified in the three exons of the new isoforms (data not shown). Using a polymorphism in exon 2 (c.95G>A), we showed that RPS6KA2a/b is also monoallelically expressed in normal ovary and heart, whereas it was uninformative for the other tissues tested (Figure 6d ). Sodium bisulphitetreated genomic DNA from placenta samples and from ovarian cancer cell lines were fully sequenced in the 2 kb CpG islands upstream of the ATG for RPS6KA2a/b and no methylated CpG was found (data not shown).
In contrast to RPS6KA2c, which has a predicted nuclear localization motif (NLS) in its first exon (sequence shown in bold italics in exon 3 0 , Figure 6a ), the new isoforms lack this. Although the algorithm for PSORT does not predict a strong NLS motif in RPS6KA2c, it has been shown previously to translocate to the nucleus upon stimulation with growth factors . Green fluorescent protein (GFP)-tagged constructs for the 'a' and 'c' isoforms were transfected in PEO4 cells, an ovarian cancer cell line. There was nuclear expression of RPS6KA2c compared to RPS6KA2a at 0.5% fetal calf serum (FCS) conditions, whereas there was clear nuclear translocation in RPS6KA2c when grown at 10% FCS (Figure 6e ). Control transfections with GFP-tagged ERK2 showed nuclear localization. This suggests that RPS6KA2c can translocate to the nucleus upon serum stimulation and a major part of the protein may be localized there, identifying the N-terminus of RPS6KA2c as an important domain.
Soft agar assays carried out with four independent clones of the inducible cell line UCI101/TR/RPS6KA2a did not showed reduced colony formation in the presence or the absence of DOX (data not shown) in contrast to cells expressing RPS6KA2c.
Discussion
Ribosomal S6 kinases are an unusual subfamily of serine-threonine kinases in the larger family of kinases. Initially, RPS6KA1 (p90 Rsk-1) and RPS6KA3 (p90 Rsk-2) were identified (Frodin and Gammeltoft, 1999) . Subsequently, RPS6KA2 (p90 Rsk-3) was isolated and more recently, RPS6KA6 (p90 Rsk-4) (Moller et al., 1994; Zhao et al., 1995; Yntema et al., 1999; Dummler et al., 2005) . RPS6KA4 (Msk-1) and RPS6KA5 (Msk-2) are less homologous to the first four members of the RSK family. The RSK family are highly conserved from Drosophila to human (Frodin and Gammeltoft, 1999) . However, orthologues of RPS6KA2 have been identified only in mouse, monkey and humans. They share an unusual structure in that, unlike other kinases, they have dual catalytic domains. The first domain is homologous to the cyclic AMP kinase family whereas the second to the phosphorylase kinase family. They code for proteins of approximately 90 kDa that act downstream of MAP kinases to transduce a variety of signals from the cell surface induced by growth factors or stress to the nucleus. Both domains contribute to growth factorstimulated autophosphorylation of RPS6KA2. A number of cellular functions for the RSK family have been proposed. These include phosphorylation of c-Fos, oestrogen receptor, nuclear factor-kappa B/IkBa, CREB, histones, Myt1, glycogen synthase kinase-3, BAD and regulation of gene expression. However, precise substrates for each member of the family are less well understood. RPS6KA3 was shown to be inactivated by mutations in the X-linked disorder Coffin-Lowry syndrome yet the highly related RPS6KA1 and RPS6KA2 kinases were found to be expressed at normal levels in these patients (Trivier et al., 1996; Bruning et al., 2000) . This has been further confirmed by the generation of RPS6KA3 À/À mice (Dufresne et al., 2001 ). The precise function of each of the RSKs (except RPS6KA3) is poorly understood partly because of the lack of specific reagents and knockout mice.
There are several lines of evidence to support that the RPS6KA2 gene is an attractive candidate to explain the high frequency of allele loss at D6S193 at 6q27. Although the cDNA start site of the original RPS6KA2 gene (RPS6KA2c) was 150 kb centromeric to D6S193, with the identification of the new isoforms (a,b), the markers D6S193 and D6S297 are now intragenic. Further, a homozygous genomic deletion of 80 kb was reported in the cell line OV167 (Lin and Morin, 2001 ), which we show has deleted exon 3 of RPS6KA2a. We have further identified another cancer cell line HEL, with homozygous deletion of the second exon of RPS6KA2a. Homozygous deletions are rare recombinant events that have been used to successfully map and identify recessive cancer genes such as PTEN and p16 (Liu and Ganesan, 2002) . They are a signpost and have been increasingly used in screening cell lines for new tumour suppressor genes (Pineau et al., 2003; Cox et al., 2005) . Further, we have examined systematically all genes in the larger interval of allele loss between D6S264 and D6S149 (1.1 Mb) and excluded others as possible candidates (Liu et al., 2002a, b) . The other candidate proposed as a class II tumour suppressor gene is the extracellular ribonuclease RNASE6PL (Trubia et al., 1997; Acquati et al., 2001) , which is the nearest gene telomeric to RPS6KA2 and maps distally to markers D6S193 and D6S297. We have examined this possibility and we were unable to confirm that it is a tumour suppressor gene (Liu et al., 2002b) .
RPS6KA2 is expressed in the normal ovary and in the ovarian epithelium as confirmed by our data and that publicly available, compared to other family members RPS6KA1 and 3. The level of expression of RPS6KA2 was relatively lower, compared to that of placenta. We attempted to confirm the cellular localization by in situ hybridization or immunohistochemistry; this was unsuccessful because of low levels of endogenous expression in a single layer of cells in the epithelium of the ovary or due to poor immunoreactivity of antibodies (K Lee et al., unpublished data). The detailed and nonoverlapping expression of the RSK1-3 in the nervous system has been reported (Zeniou et al., 2002) , reinforcing the idea that each kinase might have specialized functions. Further, using cells derived from RPS6KA3 À/À mice, several specific functions have been proposed, none of which are compensated by RPS6KA1 or RPS6KA2. In the panel of ovarian cell lines, both RT-PCR and Northern analysis confirmed relatively higher levels of transcript in the cell lines OAW28 and 41M compared to others. In the remaining cell lines, although there was undetectable levels of transcript by Northern analysis or ribonuclease protection assay (data not shown), RT-PCR detected levels of transcripts that were lower, compared to placenta, but variable compared to the HOSE cell line. However, in only the UCI101 cell line, we could demonstrate complete absence of expression by either RT-PCR or Northern analysis. The frequency of loss of expression of RPS6KA2 was around 60% in a panel of ovarian tumours. This was not related to stage, grade or histological type suggesting it may be an important candidate gene for different types of malignant ovarian tumours.
When the full-length cDNA of RPS6KA2 was ectopically expressed in ovarian cancer cell lines, it was found to suppress colony formation in 4/6 cell lines. We then chose the cell line UCI101 to perform further experiments as it does not express RPS6KA2. RPS6KA2 alone was able to inhibit colony formation in this cell line as opposed to RPS6KA1, RPS6KA3 or RPS6KA6. We have confirmed this further by inducibly expressing RPS6KA2 in UCI101 and showing that the catalytic activity is required for inhibition of growth. In contrast, in the same cell line, RNASE6PL, located telomeric to RPS6KA2, did not have any effect. We have confirmed this in other cell lines (Liu et al., 2002b) . To perform short-term experiments where the levels of expression of RPS6KA2 are high, we chose the adenoviral system, which has been used for other genes (Schreiber et al., 1999) . We confirmed that in a proliferation assay, RPS6KA2 inhibits cell growth and this is due to G1 arrest.
It has been shown for many tumour suppressor genes that reintroduction of the wild-type gene may cause increased cell death. Indirectly this was supported by the difficulty in establishing stable cell lines expressing RPS6KA2 in UCI101 or even maintaining inducible clones. The expression of adenoviral RPS6KA2 also significantly induced apoptosis in UCI101 cells compared to controls. This proves that RPS6KA2 inhibits growth of ovarian cancer cell lines and that the catalytic activity is essential for this function. Our data also suggest that it is RPS6KA2c which is essential for this effect.
Proteins involved in cell cycle control showed similar alterations in cells expressing RPS6KA2 compared with cells expressing p16, a known tumour suppressor gene. When p16 is overexpressed, cells are arrested at G1 phase (Modesitt et al., 2001; Ohtani et al., 2004) . Cyclin D1 is one of the first G1 cyclins to be expressed before the active complex with cdk4/6 is formed and they act together on Rb and its associated E2F allowing cells to progress to S phase. Reduced levels of cyclin D1 leads to the arrest of cells in G1 phase (Wilkinson and Millar, 2000) . It has been shown previously that mitogenactivated protein kinase (MAPK) cascades drive the cell cycle through G1, at least in part through modulation of expression of cyclin D1 (Lavoie et al., 1996) . Further, it has also been shown that ERKs can affect the expression of CDK inhibitors such as p21 cip1 and p27 kip1 leading to their accumulation and G1 arrest (Kawada et al., 1997; Woods et al., 1997; Schinelli et al., 2001) . It is unclear from our results the primary effect of expression of RPS6KA2; whether there is a direct effect on ERK activity or through some negative feedback. Interestingly, RPS6KA6, a related member of the family, inhibits the MAP kinase pathway (Myers et al., 2004) . RPS6KA3 has also been shown to inhibit MAP kinase cascade by negative feedback at the level of SOS (Douville and Downward, 1997) . Although the effects observed on the cell cycle proteins are similar to that observed by another bona fide tumour suppressor gene p16, the results are not conclusive. To verify this, we knocked down expression of endogenous RPS6KA2 in 41M cells and evaluated some of these parameters. Interestingly, effects of ERK, Rb, cdk and p21/p27 were exactly opposite to those observed with expression of RPS6KA2 in wild-type cells. We attempted to assess proliferation in 41M experiments using siRNA or lentivirus expressing shRNA; the results were not consistent and must await cloned stables cell lines.
The mechanism by which the expression of RPS6KA2 is reduced or absent was explored further. The hallmark of most classical tumour suppressor genes is inactivating mutations, which were not identified in RPS6KA2 in either the tumours or the cell lines. Methylation of the promoter is another possible mechanism to inactivate tumour suppressor genes (Esteller, 2002) . Indeed, HIC-1 is a gene which is methylated in many tumours without mutations (Wales et al., 1995) . HIC-1 þ /À mice develop tumours with the remaining allele being methylated to inactivate the gene (Chen et al., 2004) . The treatment of UCI101 with 5-azacytidine was found to cause reexpression of RPS6KA2 in this cell line as shown by RT-PCR. Cell lines 41M, OAW28, PEO4 and HOSE also showed an increase in expression of the transcript indicating that in these four cell lines the expression of RPS6KA2 is, in part, controlled by methylation. Interestingly, 41M was shown to have an approximate doubling of the transcript level compared to OAW28. 41M and OAW28 are the only cells in the panel of ovarian cancer cell lines to show expression of RPS6KA2, yet are apparently also partially methylated at the same locus. However, we were unable to identify methylated CpGs in the two predicted promoter regions and in any of the CpG-rich islands for the isoforms. This might be in part due to the fact that the transcriptional control of RPS6KA2 may be quite complex given the size of the gene and the alternative start codons. Direct experimental analysis of the 5 0 genomic regions will be required to identify fully all the regulatory elements.
It is increasingly recognized that at least some putative tumour suppressor genes are imprinted (Jirtle, 1999; Feinberg and Tycko, 2004) . The first such gene to be identified in ovarian and breast cancer was NOEY2/ ARH1 (Yu et al., 1999) and more recently LOT1 (Abdollahi et al., 2003) . The recent efforts to map imprinted genes in the mouse genome has contributed to the identification of additional genes that are imprinted, which occur in clusters on chromosomes (Nikaido et al., 2003; Luedi et al., 2005; Morison et al., 2005) . RPS6KA2 was not identified as an imprinted gene in any of these screens. All the isoforms of RPS6KA2 show monoallelic expression in ovarian cancer cell lines, normal ovary and heart indicating that this gene may be imprinted. Monoallelic expression may occur due to three different reasons, X-chromosome inactivation, in imprinting and randomly (Ohlsson et al., 1998; Reik and Lewis, 2005) . X-chromosome inactivation can be excluded as RPS6KA2 is located at 6q27. Monoallelic expression was detected in the ovary and in a number of other tissues and biallelically in others. The M6p/Igf2R gene is imprinted in mice but is not in humans, whereas UBE3A is monoallelically expressed in the brain but is biallelically expressed in other tissues (Kalscheuer et al., 1993; Rougeulle et al., 1997) . We could not confirm that RPS6KA2 is imprinted using DNA/RNA derived from lymphoblastoid cell lines from three independent CEPH families. Therefore, the most probable explanation for monoallelic expression of RPS6KA2 is that it is a randomly occurring event, although we sampled several normal ovaries and in each case it was expressed monoallelically (Sano et al., 2001; Lo et al., 2003; Goldmit and Bergman, 2004) . Further, when the HOSE cell line is treated with 5-azacytidine, the levels of RPS6KA2 expression are increased two-fold, suggesting silencing by methylation in one allele. In contrast, the remaining cell lines with no change in levels of expression after 5-azacytidine, can be explained by the loss of the silenced allele. Therefore, RPS6KA2 can be rendered null in tumour cells by loss or methylation of the expressed allele.
It is clear form the preliminary data that of the three isofoms, RPS6KA2c is responsible for the effect in UCI101. However, more experiments are required to confirm this. Further, the nuclear localization of RPS6KA2c compared to RPS6KA2a suggests that the first exon in RPS6KA2c is responsible for this effect, confirming earlier results .
The identification of RPS6KA2 as a recessive gene is counter-intuitive given the role of RSKs in the transduction of signals downstream of the MAP kinase pathway and their positive role in proliferation. However, recent data suggest that there may be functional differences in the RSK family. RPS6KA6 (Rsk-4) was identified recently by a RNAi screen as a gene that is important in the pathway that mediates p53-and p19-dependent proliferation arrest (Berns et al., 2004) . Additionally, it has been shown that murine Rsk-4 is an inhibitor of the FGF-RAS-ERK pathway (Myers et al., 2004) . Very little is known about the specific function of RPS6KA2. We currently do not have a detailed understanding of how RPS6KA2 negatively regulates cell growth and experiments are in progress to determine this. Further, there are examples of other serine-threonine kinases such as LKB1, MAPKAP-4 and LATS1, which are recessive genes (Teng et al., 1997; Yoo et al., 2002; Bothos et al., 2005) .
RPS6KA2 joins a group of candidate tumour suppressor genes whose loss of expression in primary ovarian tumours is not due to mutations. These include genes such as NOEY1, LOT1, DOC1 (Liu and Ganesan, 2002) . We found that loss of expression of RPS6KA2 was not restricted to a specific histological type or grade, and occurred at all stages. It is possible to speculate that given changes in other genes in the MAP kinase pathway such as Ras, BRAF in ovarian cancer, loss of RPS6KA2 expression might confer an additional growth advantage.
To further elucidate the role of RPS6KA2 in ovarian cancer, studies must be undertaken in vivo including the generation of RPS6KA2 null mice. Further analysis of the transcriptional control of RPS6KA2, and the Figure 6 Isoforms of RPS6KA2 and expression. (a) Alternative splicing of RPS6KA2 generates two different N-termini at the aminoacid level; the isoforms a and b contain a larger N-terminus whereas isoform c has a shorter sequence (exon 3 0 ) that includes a nuclear localization signal (in bold italics). The sequences encoded by each exon are shown in boxes, and annealing positions for primers specific to each isoform are shown with arrows. (b) PCR products for each of the new three exons present in RPS6KA2a/b (1, 2 and 3) amplified from genomic DNA of different cell lines (top panel). RT-PCR products for all major isoforms RPS6KA2a/b/c in the same cell lines were amplified using specific forward primers for each isoform (bottom panel). (RT-PCR for RPS6KA2a was performed with two primer sets and it is illustrated by an understroke; in the first lane with primer RSK3Expol1F and in the second lane with primer aqF; RPS6KA2b amplified with primer RSK3exon3; and RPS6KA2c, with primers NF1. All products were amplified with a common reverse primer NRI, annealing to exon 4). The last lane is for RNA integrity using GAPDH primers. Exon 2 in HEL and exon 3 in OV167 are not amplified at the DNA level, suggesting deletion of these exons. (c) Detection of RPS6KA2 isoforms in a human tissue panel. First strand cDNA from a panel of human tissues (1 ng) was used as template for PCR amplifications using primers RPS6KSA2a-qF and RPS6KA2a-qR for isoform a and NF1 and NR1 for isoform c of RPS6KA2. GAPDH primers (supplied with the cDNA panel) were used to confirm equal loading. (d) Sequence trace of DNA and RNA from normal ovary showing the polymorphism in exon 2 of RPS6KA2a present at the genomic level (G/A) but not at the RNA level (only A) (left panel) and (only G) in heart (right panel). (e) Nuclear localization of RPS6KA2. Representative fluorescence micrographs showing transfected PEO4 ovarian cancer cells expressing GFP constructs (middle panels), DNA (left panels) and merged images. After transfection, cells were grown on glass coverslips in 0.5 or 10% FCS conditions. Nuclear localization was observed for GFP-RPS6KA2c (middle two panels) in both conditions, whereas GFP-RPS6KA2a (top two panels) was mainly distributed in the cytosol and excluded from the nucleus. GFP is homogenously distributed throughout the cell whereas GFP-ERK2 is mainly targeted to the nucleus.
biochemical basis of its function in inhibiting cell growth need to be performed. It is also important to understand the relative functional differences of the isoforms of RPS6KA2 in normal and cancer cells.
Materials and methods
Materials
DNA was extracted from tumours and peripheral blood from the same patients to use as a control (Cooke et al., 1996b) . RNA from tumours and cell lines was extracted using RNeasy Mini (Qiagen, Crawley, West Sussex, UK) or RNAZolB (Biogenesis, Poole, Dorset, UK) according to the manufacturer's protocol. Human epithelial ovarian cancer cell lines were obtained from Cancer Research UK and the European Collection of Cell Cultures, and grown in culture following previously published conditions (Fuchtner et al., 1993; Laval et al., 1994) . The HOSE cell line was kindly provided by Dr S Mok (E6/E7 immortalized surface ovarian cells stabilized by hTert) (Tsao et al., 1995) . OV167 was obtained from Dr C Conover (Conover et al., 1998) .
Antibodies against Rsk-1 C-21 (sc-231), Rsk-3 C-20 (sc-1431), Rsk-3 A-16 (sc-13379), Rsk-3 N-16 (sc-13378) and Rsk-2 C-19 (sc-1430) were from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Antibodies against cell cycle proteins: cell cycle sampler kit, cyclin D1 (G124-326) and p27 (G137-524) were from BD Biosciences; Rb (4H1), p21 (DSC60) and cleaved PARP (19F4) were from Cell Signaling Technology, Danvers, MA, USA; and caspase 3 (sc-7148) was from Santa Cruz Biotechnology. HA and HA-HRP antibodies were from Roche Applied Sciences, Lewes, East Sussex, UK.
pMT2 plasmids expressing RPS6KA1 (RSK1) and RPS6KA3 (RSK2) were obtained from Dr M Greenberg (Xing et al., 1998) ; RPS6KA2 (RSK3) and K91A-RPS6KA2 (K91A-RSK3) from Dr C Bjorbaek ; and RPS6KA6 (RSK4) was obtained from Dr M Fro¨din (Dummler et al., 2005) . Full-length cDNA of RPS6KA genes were released from the pMT2 vector using EcoRI digestion and subcloned with or without a HA tag (as a linker with overhangs for restriction sites KpnI and BamHI, (CATG-TACCCATAC-GATGTTCCAGATTACGCTGGG) into the eukaryotic expression vectors, pcDNA3/neo, pcDNA3.1, pcDNA4/TO and pcDNA5/TO (Invitrogen, Paisley, Strathclyde, UK), and pEGFP-C3 (BD Biosciences). GFP-Erk2a was a gift of Dr Philip Stork (Horgan and Stork, 2003) .
Adenovirus expressing RPS6KA2 or K91A-RPS6KA2 (AdRPS6KA2 and AdK91A-RPS6KA2) were obtained by directionally subcloning the full-length cDNA from the pcDNA3/neo vectors into pShuttleCMV (Qbiogene Inc., Cambridge, Cambridgeshire, UK) using KpnI and NotI restriction sites with the HA-tag linker between BglII and KpnI sites. This transfer vector was co-transformed with the pAdEasy-1 vector (containing the adenovirus serotype 5 genome, deleted in the E1 and E3 region, Qbiogene Inc.) in BJ5183 bacterial cells. Recombinant clones were PacI-linearized and transfected in the packaging cell line QBI-293A (Qbiogene Inc.) and plaques were selected. Viral stocks were amplified and purified using BD Adeno-X Virus Purification Kit following the manufacturer's recommendations. Adenovirus expressing GFP (AdGFP) and AdRPS6KA2 were used to infect the UCI101 cell line at different multiplicity of infection values (MOIs, related to the number of viral particles used for the infection with development of cytopathic effect). MOI of 750 was found to be the optimal MOI for the majority of cells to become infected with the least toxic effect.
Adenovirus expressing p16 (Adp16) was kindly provided by Dr F Graham (Schreiber et al., 1999) . Null adenovirus was obtained from Qbiogene Inc. RPS6KA2a and RPS6KA2b isoforms were amplified from RNA extracted from 41M and HOSE ovarian cancer cell lines, respectively, using primers RPS6KA2-Vex1F and r7II. cDNA fragments were reamplified using primers HA-ATG-Vex1F and r7II to include a HindIII site for cloning and the HA tag before the start codon and digested with HindIII. The N-terminal fragment for the isoforms replaced the N-terminal of the HindIII-digested fulllength RPS6KA2 in pcDNA3.1 and pcDNA5 containing vectors. The sequences of the cloned fragments were verified by direct sequencing Primers were RPS6KA2-Vex1F: 5 0 -CCAA TCGCACAGTTGCTGGA-3 0 ; r7II: 5 0 -AAGGAGTACGCTC TCTTGTCG-3 0 and HA-ATG-Vex1F: 5 0 -CCCAAGCTTGC CACCATGTACCCATACGATGTTCCAGATTACGCTATG CCAATCGCACAGTTGCTG-3 0 ).
Northern blots
Multiple tissue Northern blot was purchased from DB Biosciences (Clontech, Cowley, Oxfordshire, UK). Ovarian cancer cell line Northern blot was prepared from mRNA from cell lines as described (Liu et al., 2002b) . Both blots were hybridized to full-length RPS6KA2 cDNA as described (Liu et al., 2002b) .
PCR, SSCP, DHPLC and sequencing PCR and SSCP were performed using standard protocols, as previously described (Liu et al., 2002b) . Individual DNA fragments were amplified from tumours or control normal DNA by PCR using specific primers. PCR products were purified and directly sequenced using BigDye terminator cycle sequencing kit v3.1 (Perkin-Elmer) on an ABI prism 377 DNA sequencer (Perkin-Elmer). DHPLC was performed using exonspecific primers as described previously (Liu et al., 2002b) . Deletions of the RPS6KA2a/b exons in the genome were detected using PCR. Primers were VEX1F: 5 0 -GAGCCGGATCTGTCCTCTC-3 0 ; VEX1R: 5 0 -TGTGCATACACAACGCAACA-3 0 ; VEX2F: 5 0 -ATCCATCTCGGACATGAAGC-3 0 ; VEX2R: 5 0 -CACGTTTGTGCATGTGTATGT-3 0 ; VEX3F: 5 0 -CTGAACGCGAAAGAAACTCC-3 0 and VEX3R: 5 0 -CACATTTTCCTGTGGAGTGG-3 0 .
Sequence of primers for each exon of RPS6KA2 are available on request.
Sodium bisulphite-treated genomic DNA from cell lines and normal tissue was obtained following the protocol of Frommer et al. (1992) and used as template for PCR. Direct sequencing of PCR products was performed as described above. As a control, placental DNA was treated with CpG methylase (M.Sss I, New England Biolabs, Hitchin, Hertfordshire, UK) and treated with sodium bisulphite and processed as above. Primers for the CpG region of both isoforms are available on request.
Reverse transcription-polymerase chain reaction RNA (0.5 mg) was used as template for RT-PCR using OneStep RT-PCR kit (Qiagen), using primers specific for each template. RT-PCR reactions were performed with the following parameters: for the cDNA synthesis, 501C for 30 min and at 951C for 15 min, followed by 10 cycles at 941C for 1 min, 601C for 30 s and at 721C for 1 min, followed by another similar 25 cycles except decreasing the annealing temperature 0.21C per cycle, and followed by 721C for 15 min. Control reactions using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used to check isolated RNA quality. Human multiple tissue panel cDNA (panels I and II) Quantitative RT-PCR For each reaction, 1 mg of RNA was reverse transcribed to cDNA with iScript Reverse Transcriptase (Bio-Rad, Hempstead, Hertfordshire, UK) using a mixture of both random hexamers and oligo-dT primers in a final volume of 20 ml. A 1/ 25 th of the RT reaction was used as a template for the PCR. Real-time quantitative polymerase chain reaction (qRT-PCR) was performed in an GeneRotor 3000 (Corbett Research, Cambridge, Cambridgeshire, UK) using primers (as before) designed to generate an amplicon of approximately 100-200 bp. Reactions were performed using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) in a 20-ml volume with the following parameters: 951C for 10 min followed by 40 cycles at 951C for 15 s, 601C for 10 s and at 721C for 30 s. Each sample was run in triplicate. Results were analysed with the software provided with the equipment (Corbett Research).
Gene expression for each signal was calculated by using the difference-in-threshold-cycle (DC t ) parameter, normalizing the levels of target gene to the levels of GAPDH in each sample. The comparative method was applied to determine the level of transcript relative to the reference, placenta or HOSE (Pfaffl, 2001) . Amplification efficiency (E) was checked for each primer pair.
Transfection and colony formation assays Eukaryotic expression vector pcDNA3 expressing RPS6KAs or empty vector as control were transfected into various cell lines using Effectene transfection reagent (Qiagen) or Lipofectamine 2000 (Invitrogen) following the manufacturer's recommendation. At 48 h post-transfection, cells were trypsinized, washed, diluted 1/10 and seeded onto 10 cm dishes in media containing G418 (400-1200 mg/ml depending on the cell line) for selection. Cells were grown for 2-3 weeks; colonies were stained with Coomassie blue (0.1% Coomassie blue, 30% methanol, 10% acetic acid) and counted. At least three experiments were performed in quadruplicate for each cell line.
Inducible stable cell lines
Stable cell lines overexpressing the gene of interest under the control of the Tet-repressor were generated using the T-REX Tetracycline-Regulated Mammalian Expression System (Invitrogen). The plasmid pcDNA6/TR for expression of the tetracycline repressor protein (TetR) has blasticidin selection.
Each gene was cloned either in pcDNA4/TO (zeocin resistance) or pcDNA5/TO (hygromycin resistance). UCI101 cells were transfected simultaneously or sequentially with the repressor and expression vectors using Lipofectamine 2000 (Qiagen) following the manufacturer's recommendation. Transfected cells were selected in the presence of 5 mg/ml blasticidin and 100 mg/ml zeocin or 200 mg/ml hygromycin for 2-3 weeks. Individual clones were isolated, expanded and assayed for the expression of the transfected gene only in the presence of tetracycline or DOX using Western blotting.
Anchorage-independent growth Cell suspension (1 ml) or One of inducible stable cell lines was mixed with 1 ml of tissue culture media with DOX containing 0.7% agar to result in a final concentration of 1250 and 2500 cells/ml. The cell suspension was immediately plated in 35 mm plates coated with 2 ml of 1% agar in medium (Dulbecco's modified Eagle's medium DMEM 10% FCS) and cultured at 371C with 5% CO 2 , replenishing the media in the top layer every 2 days. Control cultures were set in parallel without the addition of DOX in the media. After 2 weeks, the top layer of the culture was stained with crystal violet solution (0.005% p-iodonitrotetrazolium violet (Sigma, Poole, Dorset, UK), 50% methanol). Soft agar assays were analysed in triplicate for each experiment, and colonies containing more than 50 cells were counted. At least three experiments were performed for each cell line.
Cell lysis, immunoprecipitation and Western blotting
Washed cells were lysed with lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM ethylene diaminetetraacetic acid (EDTA), 1 mM ethylene glycol-bis (b-aminoethyl ether) N,N,N 0 ,N 0 -tetraacetic acid (EGTA), 0.5% NP-40, 1% Triton X-100 at pH 7.4, supplemented with Complete protease inhibitor tablets (Roche)) and incubated on ice for 30 min. Lysate was clarified by centrifugation at 41C, 16 000 g for 30 min. Protein concentration was assessed and samples prepared by the addition of 5 Â Laemmli sample buffer (Laemmli, 1970) . For immunoprecipitations, the cleared lysate was incubated with 200 ng of antibody and Protein G-beads (Amersham Pharmacia, Little Chalfont, Buckinghamshire, UK) overnight at 41C with gentle shaking. Beads were washed twice with lysis buffer, resuspended in 1 Â Laemmli buffer and denatured. Proteins from immunoprecipitations or total cell lysates were resolved in 8 or 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (Laemmli, 1970) , transferred to nitrocellulose membrane and immunoblotted using standard techniques.
Azacytidine treatment
Ovarian cancer cell lines were plated onto 10 cm dishes at a density of 2-5 Â 10 5 cells. Freshly prepared 5-azacytidine was added to the medium to a final concentration of either 1-5 mM for UCI101 or at 5 mM for other cell lines, whereas no drug was added to control cells. Medium was changed 2 days later with fresh addition of the 5-azacytidine and cells were harvested after 4-5 days and RNA extracted for RT-PCR analysis.
Proliferation assay 2000 cells were plated onto a 96-well plate in DMEM 10% FCS and left to adhere. The medium was changed to DMEM 0.1% FCS and 24 h later, adenovirus was added to the cells (MOI 750). Proliferation was measured by staining cells with crystal violet solution (0.5% p-iodonitrotetrazolium violet, 50% methanol). Excess stain was washed, the absorbed stain was extracted in acidic solution (10% acetic acid) and the absorbance was measured at 562 nm. Proliferation of cells was assessed by the increase in the absorbance relative to day 0. At least three experiments were performed in quadruplicate.
Cell cycle analysis 5 Â 10 5 UCI101 cells in DMEM 5% FCS were infected with adenovirus (MOI 750) for 48 h. Then, 1 Â 10 6 cells were fixed in 70% ethanol for 30 min at 41C. After fixation, the cells were washed twice with PBS and resuspended in 1 ml of PBS with 50 mg/ml propidium iodide (PI) and 100 mg/ml RNAse A (Sigma). Cells were analysed by FACS (Becton Dickenson, Cowley, Oxfordshire, UK) using CellQuest software v3.3. A total of 10 000 single events were recorded each time, and the percentage of cells in G1, G2 and S phases were calculated. The experiments were repeated at least three times for each variable.
For immunodetection of cell cycle proteins, 5 Â 10 5 UCI101 cells in DMEM 5% FCS were infected with adenovirus (MOI 750) for 72 h. Cells were lysed in RIPA buffer (150 mM NaCl, 20 mM Na-phosphate, pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 5 mM EDTA, 10 mM NaF, supplemented with Complete protease inhibitor tablets (Roche) and phosphatases inhibitors I and II (Sigma)); lysates were cleared by centrifugation. Protein concentration was determined using BCA assay (Pierce, Perbio Science UK Ltd, Cramlington, Northumberland, UK) and 50 mg of lysate was used for Western blotting.
Apoptosis
The induction of apoptosis by RPS6KA2 was assessed by the CaspaTag assay according to the manufacturer's instructions (Intergen, Oxford, Oxfordshire, UK). This method is based on the carboxyflourescein-labelled fluoromethyl ketone (FMK)-peptide inhibitors of caspases. 5 Â 10 5 UCI101 cells in DMEM 5% FCS were infected with adenovirus (MOI 750) for 72 h. Cells were detached and was labelled with FAM-VAD-FMK (carboxyflourescein derivative of benzyloxycarbonyl valyalanyl aspartic acid flouromethyl ketone). PI was added to the labelled cells to stain necrotic, dead and membrane compromised cells. Cells were analysed by FACS collecting 10 000 events. A log FL1 (X-axis) versus log FL3 (Y-axis) dot plot was generated. Apoptotic cells are fluorescein positive, PI negative cells (caspase positive, living cells) located in the bottom right quadrant.
RNA interference 41M cells were transfected with Lipofectamine 2000 and oligos siRNA following the manufacturer's procotol for reverse transfections. siRNA oligo-Lipofectamine 2000 complexes were prepared with 100 pmol siRNA oligo in 0.5 ml of OptiMem media (Invitrogen) in wells of a 6-well/plate. Cell suspension of 41M cells in DMEM 10% FCS media (without antibiotics) were added to the wells at a density of 3.5 Â 10 5 cells/well in a final volume of 2.5 ml. Medium was changed after 8 h and cells were grown for 2-4 days. Mock transfections were carried out in parallel using control siRNA and siRNA buffer instead of oligo siRNA.
For quantification of knockdown, 48 h after transfection, cells were harvested, washed with PBS and total RNA was extracted by using RNeasy mini kit (Qiagen), eluting the RNA from the column in 40 ml of RNase-and DNase-free water. RSP6KA2 transcript was quantified using qRT-PCR. For immunoblot analysis, 4 days after transfection, cells were harvested, washed with PBS and lysed in RIPA buffer. Protein concentration was determined using BCA assay (Pierce), 20 mg of lysate was used for Western blotting and immunodetection of cell cycle proteins was carried out as before.
Target-specific siRNA duplexes were designed and purchased from Eurogentec SA (Southampton, Hampshire, UK) and MWG Biotech AG (Covent Garden, London, UK). Working dilutions were prepared in siRNA buffer (MWG Biotech) at 20 mM. Fluorescence microscopy PE04 ovarian cancer cells were transfected using Lipofectamine 2000 with GFP constructs expressing RPS6KA2a and c, ERK2 or GFP alone, in 24-well/plates using 0.5 mg of plasmid. After transfection for 24 h, cells were detached with EDTA (3 mM), washed and replated on glass coverslips in 24-well plates at a density of 75 000 cells/ml in media, and after 8 h, medium was replaced by DMEM 0.5% FCS or DMEM 10% FCS and grown overnight. Cells were fixed and nuclei were stained with Hoechst 33 342 at 5 mg/ml (Sigma). Coverslips were mounted with SlowFade Light Antifade Kit (Molecular Probes, Paisley, Strathclyde, UK); images were acquired using a Zeiss Axioskop 2 plus (Zeiss, Welwyn Garden City, Hertfordshire, UK) fluorescent microscope equipped with a Â 63 Plan Apochromat 1.3 NA objective, a GFP filter set and processed with Photoshop software (Adobe, Uxbridge, Middlesex, UK).
